Bladder cancer - historical
Revision as of 12:22, 15 July 2024 by Warner-admin (talk | contribs) (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''")
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main bladder cancer page for current regimens.
2 regimens on this page
2 variants on this page
|
Nonmuscle invasive bladder cancer
Intravesicular Doxorubicin monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Martínez-Piñeiro et al. 1990 | 1980-1988 | Phase 3 (C) | 1. BCG | Inferior RFS |
2. Thiotepa | Not reported | |||
Lamm et al. 1991 (SWOG 8216) | 1983-1985 | Phase 3 (C) | BCG | Seems to have inferior DFS |
Chemotherapy
- Doxorubicin (Adriamycin) 50 mg intravesicularly once on day 1
7-day cycle for 5 cycles, then 30-day cycle for 11 cycles (approximately 1 year)
References
- Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. link to original article contains partial protocol PubMed
- SWOG 8216: Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991 Oct 24;325(17):1205-9. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Intravesicular Thiotepa monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Martínez-Piñeiro et al. 1990 | 1980-1988 | Phase 3 (C) | 1. BCG | Inferior RFS |
2. Doxorubicin | Not reported |
Chemotherapy
- Thiotepa (Thioplex) 50 mg intravesicularly x 15 treatments
References
- Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. link to original article contains partial protocol PubMed